Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 mild to moderatesome concern
1190/1054 conclusif
  • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
atypical endpoints without correspondence with those of the others trials
ATTACC, ACTIV-4a, and REMAP-CAP, noncritically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
1190/1054 conclusif
  • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
atypical endpoints without correspondence with those of the others trials
RAPID (Sholzberg), 2021
 
NCT04362085
RCTheparin at therapeutic dosestandard of careCOVID-19 mild to moderatesome concern
228/237 suggested
  • suggested 78 % decrease in deaths,death D28 with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 31 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).